Drug intelligence / Profile preview

Abaxil

Development stage: Unknown
Lead developer: Saffron Pharma
Modality: Small Molecules
Administration: Oral

Overview

Abaxil is an anticoagulant medication developed and marketed by Saffron Pharma in Pakistan. It contains apixaban, a small molecule direct oral anticoagulant (DOAC). Apixaban acts as a selective, reversible, and direct inhibitor of Factor Xa, both free and clot-bound, as well as prothrombinase activity. By inhibiting Factor Xa, Abaxil prevents the conversion of prothrombin to thrombin, thereby inhibiting thrombus development. It is indicated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, the prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) following hip or knee replacement surgery, and the treatment and prevention of recurrence of DVT and PE.

Brand names: Abaxil

Targets

F10 (Factor Xa)

Beyond the preview

Go deeper on Abaxil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Abaxil.

Explore the full profile